Alternative donor hematopoietic stem cell transplantation: A role for umbilical cord blood transplantation for hematologic malignancies

Laura Newell, Jonathan A. Gutman, Colleen Delaney

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Hematopoietic stem cell transplantation (HSCT) is a widely accepted therapy with potentially curative benefit for patients with benign and malignant hematologic disorders. There are currently three possible sources of allogeneic hematopoietic stem cells (HSCs) - bone marrow, granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood (PBSC), and umbilical cord blood (CB). Donors can be either related or unrelated and must match recipients at human leukocyte antigens (HLA). Based on the average size of American families, and the 25% probability that a given sibling pair will be HLA-matched, it is estimated that approximately 35% of persons in the United States will have an HLA-matched sibling.

Original languageEnglish (US)
Title of host publicationLeukemia and Related Disorders
Subtitle of host publicationIntegrated Treatment Approaches
PublisherSpringer New York
Pages219-249
Number of pages31
ISBN (Electronic)9781607615651
ISBN (Print)9781607615644
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Keywords

  • Alternative donor
  • Bone marrow
  • Granulocyte colony-stimulating factor
  • Hematopoietic stem cell transplantation
  • Leukemia
  • Mobilized peripheral blood
  • Stem cells
  • Transplantation
  • Umbilical cord blood

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Alternative donor hematopoietic stem cell transplantation: A role for umbilical cord blood transplantation for hematologic malignancies'. Together they form a unique fingerprint.

Cite this